1
|
Gagaille MP, Leclerc V, Allard J, Marty F, Treguier B, Bonnet M, Pons-Kerjean N. Qualification and impact of a video-assisted control system in a chemotherapy compounding unit. Eur J Hosp Pharm 2023:ejhpharm-2023-003692. [PMID: 37076270 DOI: 10.1136/ejhpharm-2023-003692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Accepted: 03/14/2023] [Indexed: 04/21/2023] Open
Abstract
OBJECTIVES Anticancer drug preparation control is essential to ensure quality and patient safety. Drugcam (Eurekam Company) is a digital video-assisted control system based on artificial intelligence methods to identify vials used and volumes withdrawn. As for any control system, qualification is required before use in a chemotherapy compounding unit (CCU). METHODS We conducted an operational qualification (sensitivity, specificity and accuracy assessment of vials and volumes recognition and quantitative analysis of measured volumes) and a performance qualification (comparison with visual control) of Drugcam in our CCU, as well as an impact study on compounding time and compound supply time. RESULTS Sensitivity, specificity and accuracy of vials (94%, 98% and 96%, respectively) and volumes (86%, 96% and 91%, respectively) recognition are satisfactory. It depends on both the object presented and the camera tested. False positives, which could lead to release of non-compliant preparation, were detected. Volume reading errors may exceed the tolerance threshold of ±5% for small volumes. Drugcam did not significantly lengthen compounding time and compound supply time. CONCLUSIONS No recommendations for a qualification method of this new type of control equipment exist. However, a qualification process is essential to understand tool limitations and integrate them into the CCU risk management system. Drugcam enables anticancer drug preparation to be secure and is also useful for initial and continuous staff training.
Collapse
|
2
|
Saint-Lorant G, Vasseur M, Allorge D, Beauval N, Simon N, Odou P. Four-year follow-up of surface contamination by antineoplastic drugs in a compounding unit. Occup Environ Med 2023; 80:146-153. [PMID: 36717254 DOI: 10.1136/oemed-2022-108623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Accepted: 12/21/2022] [Indexed: 01/31/2023]
Abstract
OBJECTIVES This study aimed to monitor the contamination by antineoplastic drugs on work surfaces in a compounding unit 4 years after its implementation. METHODS This descriptive study was done in a unit performing on average 45 000 preparations per year. Surface sampling points (N=23) were monitored monthly in the frame of routine activity from the opening of an anticancer drug compounding unit. Contamination with nine antineoplastic drugs (cyclophosphamide, ifosfamide, dacarbazine, 5-fluorouracil, methotrexate, gemcitabine, cytarabine, irinotecan and doxorubicin) was assessed on wipes with a local liquid chromatography coupled with a tandem mass spectrometer analysis. The contamination rate (CR, %) was prospectively monitored every month during the entire study period. The occurrence of critical incidents was also registered. The effect of each safety measure implemented during this period was also analysed. RESULTS Based on the 1104 samples collected between March 2016 and March 2020, the CR was 18.5%. If three different critical incidents among a vial breakage that occurred were individually considered, this CR was slightly lower than that in the literature. Eight months after opening and taking different corrective actions, the overall CR dropped from 42.39% to 11.52% (p<0.001). Contamination was limited to the area that includes the compounding room and, more precisely, the welder and the QC-Prep+ sampling points. CONCLUSIONS From the beginning of the study and from month to month, surface contamination was limited to the nearest sampling points to the compounding unit. This 4-year monitoring study allowed us to determine the intravenous conventional antineoplastic drugs and sampling points to be focused on.
Collapse
Affiliation(s)
- Guillaume Saint-Lorant
- ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University of Lille, Lille, France .,Pharmacy, CHU Caen, Caen, France
| | - Michèle Vasseur
- ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University of Lille, Lille, France.,Pharmacy, CHU Lille, Lille, France
| | - Delphine Allorge
- ULR-4483-IMPECS-IMPact de l'Environnement Chimique sur la Santé humaine, University of Lille, Lille, France.,CHRU, Lille, France
| | | | - Nicolas Simon
- ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University of Lille, Lille, France.,Pharmacy, CHU Lille, Lille, France
| | - Pascal Odou
- ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University of Lille, Lille, France.,Pharmacy, CHU Lille, Lille, France
| |
Collapse
|
3
|
Rayyad A, Makki AA, Chourpa I, Massot V, Bonnier F. Quantification of clinical mAb solutions using Raman spectroscopy: Macroscopic vs microscopic analysis. Talanta 2022; 250:123692. [PMID: 35777345 DOI: 10.1016/j.talanta.2022.123692] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Revised: 06/09/2022] [Accepted: 06/13/2022] [Indexed: 11/28/2022]
Abstract
Raman Spectroscopy is well emerged in the field of Analytical Quality Control (AQC) as a rapid and cost-effective technique useful in many applications. The advantage of Raman spectroscopy is the non-invasiveness of measurements that enablesto analyse samples directly in its container. In this study, the potential of Raman spectroscopy was investigated for analysis of clinical preparations of mAbs. Three commercial formulations of monoclonal antibodies (mAbs) Avastin®, Ontruzant® and Tecentriq® corresponding to Bevacizumab (BVC), Trastuzumab (TRS) and Atezolizumab (ATZ) respectively, were analysed in quartz cuvette in macroscopic analysis and through the wall of perfusion bags in microscopic analysis. The spectra have been compared to those of excipients (trehalose and sucrose) and of γ-Globulin, in order to investigate the origin of Raman bands. As expected, Raman spectra were a combination of bands from monoclonal antibodies and correspoding excipients found in formulas. For quantitative analysis of the solutions, models have been constructed using Partial Least Square Regression (PLSR) with Leave K-Out Cross Validation (LKOCV). The quantification performance was comparable for both macroscopic and microscopic analysis, in terms of error and linearity. The results are thus promising for future AQC in situ, in perfusion bags.
Collapse
Affiliation(s)
- Ayyoub Rayyad
- EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, 31 Avenue Monge, 37200, Tours, France
| | - Alaa A Makki
- University of Gezira, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, P.O. Box 20, 21111, Wad Madani, Sudan
| | - Igor Chourpa
- EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, 31 Avenue Monge, 37200, Tours, France
| | - Victor Massot
- CHU de Tours, Unité de Biopharmacie Clinique Oncologique, Pharmacie, France
| | - Franck Bonnier
- EA 6295 Nanomédicaments et Nanosondes, Faculté de Pharmacie, Université de Tours, 31 Avenue Monge, 37200, Tours, France.
| |
Collapse
|
4
|
Trends in pharmaceutical analysis and quality control by modern Raman spectroscopic techniques. Trends Analyt Chem 2022. [DOI: 10.1016/j.trac.2022.116623] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
5
|
Hrichi H, Kouki N, Tar H. Analytical methods for the quantification of cisplatin, carboplatin, and oxaliplatin in various matrices over the last two decades. CURR PHARM ANAL 2021. [DOI: 10.2174/1573412918666210929105058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Platinum derivatives including cisplatin and its later generations carboplatin, and oxaliplatin remain the most largely used drugs in the therapy of malignant diseases. They exert notable anticancer activity towards numerous types of solid tumors such as gastric, colorectal, bladder, ovary, and several others. The chemotherapeutic activity of these compounds, however, is associated with many unwanted side effects and drug resistance problems limiting their application and effectiveness. Proper dosage is still an inherent problem, as these drugs are usually prescribed in small doses.
Objective:
Several analytical methods have been reported for the accurate quantification of cisplatin, carboplatin, and oxaliplatin and their metabolites either alone or in combination with other chemotherapeutic drugs, in different matrices such as pharmaceutical formulations, biological fluids, cancer cells, and environmental samples. The main goal of this review is to systematically study the analytical methods already used for the analysis of cisplatin, carboplatin, and oxaliplatin in various matrices during the last two decades.
Results and Conclusion:
In the literature, reviews showed that numerous analytical methods such as electroanalytical, UV-visible spectrophotometry, chromatographic, fluorescence, atomic absorption spectrophotometry, and other spectroscopic methods combined with mass spectrometry were used for the determination of these compounds in various matrices.
Collapse
Affiliation(s)
- Hajer Hrichi
- Chemistry Department, College of Science, Jouf University, P.O. Box: 2014, Sakaka, Saudi Arabia
| | - Noura Kouki
- Chemistry Department, College of Science and Arts, Qassim University, Buraidah, P.O. Box: 51911, Saudi Arabia
| | - Haja Tar
- Chemistry Department, College of Science and Arts, Qassim University, Buraidah, P.O. Box: 51911, Saudi Arabia
| |
Collapse
|
6
|
Makki AA, Elderderi S, Massot V, Respaud R, Byrne HJ, Tauber C, Bertrand D, Mohammed E, Chourpa I, Bonnier F. In situ Analytical Quality Control of chemotherapeutic solutions in infusion bags by Raman spectroscopy. Talanta 2021; 228:122137. [PMID: 33773705 DOI: 10.1016/j.talanta.2021.122137] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Revised: 01/17/2021] [Accepted: 01/18/2021] [Indexed: 02/04/2023]
Abstract
Analytical Quality Control (AQC) in centralised preparation units of oncology centers is a common procedure relying on the identification and quantification of the prepared chemotherapeutic solutions for safe intravenous administration to patients. Although the use of Raman spectroscopy for AQC has gained much interest, in most applications it remains coupled to a flow injection analyser (FIA) requiring withdrawal of the solution for analysis. In addition to current needs for more rapid and cost-effective analysis, the risk of exposure of clinical staff to the toxic molecules during daily handling is a serious concern to address. Raman spectroscopic analysis, for instance by Confocal Raman Microscopy (CRM), could enable direct analysis (non-invasive) for AQC directly in infusion bags. In this study, 3 anticancer drugs, methotrexate (MTX), 5-fluorouracil (5-FU) and gemcitabine (GEM) have been selected to highlight the potential of CRM for withdrawal free analysis. Solutions corresponding to the clinical range of each drug were prepared in 5% glucose and data was collected from infusion bags placed under the Raman microscope. Firstly, 100% discrimination has been obtained by Partial Least Squares Discriminant Analysis (PLS-DA) confirming that the identification of drugs can be performed. Secondly, using Partial Least Squares Regression (PLSR), quantitative analysis was performed with mean % error of predicted concentrations of respectively 3.31%, 5.54% and 8.60% for MTX, 5-FU and GEM. These results are in accordance with the 15% acceptance criteria used for the current clinical standard technique, FIA, and the Limits of Detection for all drugs were determined to be substantially lower than the administered range, thus highlighting the potential of confocal Raman spectroscopy for direct analysis of chemotherapeutic solutions.
Collapse
Affiliation(s)
- Alaa A Makki
- Université de Tours, EA 6295 Nanomédicaments et Nanosondes, 31 Avenue Monge, 37200, Tours, France; University of Gezira, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, P.O. Box 20, 21111, Wad Madani, Sudan
| | - Suha Elderderi
- Université de Tours, EA 6295 Nanomédicaments et Nanosondes, 31 Avenue Monge, 37200, Tours, France; University of Gezira, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, P.O. Box 20, 21111, Wad Madani, Sudan
| | - Victor Massot
- CHU de Tours, Unité de Biopharmacie Clinique Oncologique, Pharmacie, France
| | - Renaud Respaud
- Université de Tours, UMR 1100, CHRU de Tours, Service de Pharmacie, F-37032, Tours, France
| | - Hugh J Byrne
- FOCAS Research Institute, TU Dublin, City Campus, Kevin Street, Dublin 8, Ireland
| | - Clovis Tauber
- Université de Tours, INSERM UMR 1253 IBrain, 37000, Tours, France
| | | | - Elhadi Mohammed
- University of Gezira, Faculty of Pharmacy, Medicinal and Aromatic Plants Research Center (MAPRC), P.O. Box 20, 21111, Wad Madani, Sudan
| | - Igor Chourpa
- Université de Tours, EA 6295 Nanomédicaments et Nanosondes, 31 Avenue Monge, 37200, Tours, France
| | - Franck Bonnier
- Université de Tours, EA 6295 Nanomédicaments et Nanosondes, 31 Avenue Monge, 37200, Tours, France.
| |
Collapse
|
7
|
El Orche A, Adade CA, Mefetah H, Cheikh A, Karrouchi K, El Karbane M, Bouatia M. Chemometric Analysis of UV-Visible Spectral Fingerprints for the Discrimination and Quantification of Clinical Anthracycline Drug Preparation Used in Oncology. BIOMED RESEARCH INTERNATIONAL 2021; 2021:5580102. [PMID: 34041297 PMCID: PMC8121585 DOI: 10.1155/2021/5580102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 04/12/2021] [Accepted: 04/29/2021] [Indexed: 11/17/2022]
Abstract
In clinical treatment, the analytical quality assessment of the delivery of chemotherapeutic preparations is required to guarantee the patient's safety regarding the dose and most importantly the appropriate anticancer drug. On its own, the development of rapid analytical methods allowing both qualitative and quantitative control of the formulation of prepared solutions could significantly enhance the hospital's workflow, reducing costs, and potentially providing optimal patient care. UV-visible spectroscopy is a nondestructive, fast, and economical technique for molecular characterization of samples. A discrimination and quantification study of three chemotherapeutic drugs doxorubicin, daunorubicin, and epirubicin was conducted, using clinically relevant concentration ranges prepared in 0.9% NaCl solutions. The application of the partial least square discriminant analysis PLS-DA method on the UV-visible spectral data shows a perfect discrimination of the three drugs with a sensitivity and specificity of 100%. The use of partial least square regression PLS shows high quantification performance of these molecules in solution represented by the low value of root mean square error of calibration (RMSEC) and root mean square error of cross validation (RMSCECV) on the one hand and the high value of R-square on the other hand. This study demonstrated the viability of UV-visible fingerprinting (routine approach) coupled with chemometric tools for the classification and quantification of chemotherapeutic drugs during clinical preparation.
Collapse
Affiliation(s)
- Aimen El Orche
- Laboratory of Chemical Processes and Applied Materials, Faculty of Science and Technology, Sultan Moulay Slimane University, Beni-Mellal, Morocco
| | - Casimir Adade Adade
- Team of Formulation and Quality Control of Health Products, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Hafid Mefetah
- Rabat Pediatrics Hospital, Ibn Sina University Hospital Center, Rabat, Morocco
| | - Amine Cheikh
- Departement of Pharmacy, Faculty of Pharmacy, Abulcasis University, Rabat, Morocco
| | - Khalid Karrouchi
- Team of Formulation and Quality Control of Health Products, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Miloud El Karbane
- Team of Formulation and Quality Control of Health Products, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Mustapha Bouatia
- Team of Formulation and Quality Control of Health Products, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| |
Collapse
|
8
|
Quality control of cytostatic drug preparations-comparison of workflow and performance of Raman/UV and high-performance liquid chromatography coupled with diode array detection (HPLC-DAD). Anal Bioanal Chem 2021; 413:2587-2596. [PMID: 33624127 DOI: 10.1007/s00216-021-03223-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Revised: 01/11/2021] [Accepted: 02/06/2021] [Indexed: 10/22/2022]
Abstract
The drugs used for treatment during chemotherapy are manufactured individually for each patient in specialised pharmacies. Thorough quality control to confirm the identity of the delivered active pharmaceutical ingredient and the final concentration of the prepared application solution is not standardized yet except for optical or gravimetric testing. However, solution stability problems, counterfeit drugs, and erroneous or deliberate underdosage may occur and negatively influence the quality of the product and could cause severe health risks for the patient. To take a step towards analytical quality control, an on-site analytical instrument using Raman and UV absorption spectroscopy was employed and the results were compared to high-performance liquid chromatography coupled to diode array detection. Within the scope of the technology evaluation, the uncertainty of measurement was determined for the analysis of the five frequently used cytostatic drugs 5-fluorouracil, cyclophosphamide, gemcitabine, irinotecan and paclitaxel. The Raman/UV technique (2.0-3.2% uncertainty of measurement; level of confidence: 95%) achieves a combined uncertainty of measurement comparable to HPLC-DAD (1.7-3.2% uncertainty of measurement; level of confidence: 95%) for the substances 5-fluorouracil, cyclophosphamide and gemcitabine. However, the uncertainty of measurement for the substances irinotecan and paclitaxel is three times higher when the Raman/UV technique is used. This is due to the fact that the Raman/UV technique analyses the undiluted sample; therefore, the sample has a higher viscosity and tendency to foam. Out of 136 patient-specific preparations analysed within this study, 96% had a deviation of less than 10% from the target content.
Collapse
|
9
|
Cornet L, Gervaise C, Hugues M, Menguy S, Macé A, Tinquaut F, Forges F, Simoens X. How human activity impacted manufacturing non-compliances: A multivariate analysis in a centralized cytotoxic preparation unit. J Oncol Pharm Pract 2020; 27:1896-1903. [PMID: 33203300 DOI: 10.1177/1078155220973065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
INTRODUCTION The aim of the study was to identify risk factors related to human errors in the preparation of anticancer drugs in order to improve the pharmaceutical process by setting corrective actions. METHOD Risk factors which could increase the probability of error were identified: daily workload, workload on the previous day and subcontractors' workload, time slot of the preparation, understaffing, incidents which could affect workflow, individual experience of technicians and cleanrooms layout. Drug reconstitution or complex fabrications were also considered as risk factors. We used univariate and multivariate logistic regression analyses to screen for correlation between risks and errors. RESULT Among 11 278 preparations analyzed, 115 were non-compliant. Univariate analysis shows significant variables: individual experience of technicians, technicians working in the same cleanrooms and technicians' rotations. 2 technicians are significantly associated with a higher risk of error and 5 with a lower risk. The multivariate analysis confirmed the conclusions of the univariate. DISCUSSION As expected, time slot of the manufacture, cleanrooms layout and some technicians increase the risk of error. Surprisingly, technicians' experience led to increase the risk. This study is a first approach to evaluate the human error aspect in non-compliant preparations, in order to optimize security of antineoplastic drugs preparations.
Collapse
Affiliation(s)
- Lucie Cornet
- Department of Pharmacy, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
| | - Caroline Gervaise
- Department of Pharmacy, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
| | - Marion Hugues
- Department of Pharmacy, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
| | - Sandrine Menguy
- Department of Pharmacy, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
| | - Agnès Macé
- Department of Pharmacy, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
| | | | - Fabien Forges
- Department of Pharmacy, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
| | - Xavier Simoens
- Department of Pharmacy, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
| |
Collapse
|
10
|
Yang W, Knorr F, Popp J, Schie IW. Development and evaluation of a hand-held fiber-optic Raman probe with an integrated autofocus unit. OPTICS EXPRESS 2020; 28:30760-30770. [PMID: 33115070 DOI: 10.1364/oe.401207] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Accepted: 09/22/2020] [Indexed: 05/23/2023]
Abstract
Current implementations of fiber-optic Raman spectroscopy probes are frequently based on non-contact probes with a fixed focus and thus and have to precisely maintain the probe-to-sample distance to ensure a sufficient signal collection. We propose and experimentally demonstrate a novel hand-held fiber-optic Raman probe design, which is based on a liquid lens autofocusing unit, combined with a distance sensor and an in-house developed algorithm to precisely determine the probe-to-sample distance. The reported probe significantly improves the signal stability even for hand-held operation, while reducing distance-dependent artifacts for the acquisition of Raman spectra and can improve the acquisition of Raman spectra in a variety of applications.
Collapse
|
11
|
Krtalić A, Miljković V, Gajski D, Racetin I. Spatial Distortion Assessments of a Low-Cost Laboratory and Field Hyperspectral Imaging System. SENSORS 2019; 19:s19194267. [PMID: 31581472 PMCID: PMC6806291 DOI: 10.3390/s19194267] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 09/22/2019] [Accepted: 09/29/2019] [Indexed: 11/16/2022]
Abstract
This article describes the adaptation of an existing aerial hyperspectral imaging system in a low-cost setup for collecting hyperspectral data in laboratory and field environment and spatial distortion assessments. The imaging spectrometer system consists of an ImSpector V9 hyperspectral pushbroom scanner, PixelFly high performance digital CCD camera, and a subsystem for navigation, position determination and orientation of the system in space, a sensor bracket and control system. The main objective of the paper is to present the system, with all its limitations, and a spatial calibration method. The results of spatial calibration and calculation of modulation transfer function (MTF) are reported along with examples of images collected and potential uses in agronomy. The distortion value rises drastically at the edges of the image in the near-infrared segment, while the results of MTF calculation showed that the image sharpness was equal for the bands from the visible part of the spectrum, and approached Nyquist's theory of digitalization. In the near-infrared part of the spectrum, the MTF values showed a less sharp decrease in comparison with the visible part. Preliminary image acquisition indicates that this hyperspectral system has potential in agronomic applications.
Collapse
Affiliation(s)
- Andrija Krtalić
- Faculty of Geodesy, University of Zagreb, 10000 Zagreb, Croatia.
| | - Vanja Miljković
- Faculty of Geodesy, University of Zagreb, 10000 Zagreb, Croatia
| | - Dubravko Gajski
- Faculty of Geodesy, University of Zagreb, 10000 Zagreb, Croatia
| | - Ivan Racetin
- Faculty of Civil Engineering, Architecture and Geodesy, University of Split, 21000 Split, Croatia
| |
Collapse
|
12
|
Makki AA, Bonnier F, Respaud R, Chtara F, Tfayli A, Tauber C, Bertrand D, Byrne HJ, Mohammed E, Chourpa I. Qualitative and quantitative analysis of therapeutic solutions using Raman and infrared spectroscopy. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2019; 218:97-108. [PMID: 30954803 DOI: 10.1016/j.saa.2019.03.056] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2018] [Revised: 02/06/2019] [Accepted: 03/17/2019] [Indexed: 06/09/2023]
Abstract
Anticancer drugs are prescribed and administrated to an increasing number of patients on a daily basis. As a consequence, a number of concerns have been raised about the patient health and safety in the case that the drugs administered are not at the required concentration or even worse not the correct ones. Quality control of therapeutic solutions has therefore been extensively implemented in hospital environments, in order to avoid any failure in the intense workflow faced by administering pharmacists. In the present study, infrared (IR) and Raman spectroscopy have been employed for the analysis of 3 commercially available therapeutic solutions TEVA®, MYLAN®, CERUBIDINE®, respectively containing doxorubicin, epirubicin and daunorubicin. They perfectly illustrate the analytical difficulties encountered, as these 3 chemotherapeutic drugs are isomers, hardly distinguishable with conventional approaches such as UV/VIS spectrometry. Any analytical failure to identify these molecules can lead to delays in patient treatment. While Partial Least Squares Regression analysis demonstrates that both Raman and IR can deliver satisfactory quantitative analysis in the clinical range, with respective Root Mean Square Error of Cross Validation (RMSECV) between 0.0127 - 0.0220 g·L-1 and 0.0573 - 0.0759 g·L-1, the identification rate between the 2 techniques differs substantially. Indeed, Principal Component Analysis - Factorial Discriminant Analysis (PCA-FDA) highlights that, depending on the data preprocessing applied to Raman spectra, the discrimination between the 3 drugs is decreased, with in some cases specificity and sensitivity below 50%. However, IR analysis displays encouraging results with an overall specificity and sensitivity between 99 and 100%, suggesting that reliable validation of the therapeutic solution for administration to patients can be achieved. IR and Raman spectroscopy could assist and support quality control of chemotherapeutic solutions prepared in personalised concentrations for each patient. The effective and reliable characterisation of therapeutic solutions could have a lot to offer to improve current practices in a near future.
Collapse
Affiliation(s)
- Alaa A Makki
- Université François-Rabelais de Tours, EA 6295 Nanomédicaments et Nanosondes, 31 avenue Monge, 37200 Tours, France; Department of Pharmacognosy, Faculty of Pharmacy, University of Gezira, Sudan
| | - Franck Bonnier
- Université François-Rabelais de Tours, EA 6295 Nanomédicaments et Nanosondes, 31 avenue Monge, 37200 Tours, France.
| | - Renaud Respaud
- Université François-Rabelais de Tours, UMR 1100, CHRU de Tours, Service de Pharmacie, F-37032 Tours, France
| | - Fatma Chtara
- Université François-Rabelais de Tours, EA 6295 Nanomédicaments et Nanosondes, 31 avenue Monge, 37200 Tours, France
| | - Ali Tfayli
- U-Psud, University of Paris-Saclay, Lip (Sys)2, EA7357, UFR-Pharmacy, Châtenay-Malabry, France
| | - Clovis Tauber
- UMR U1253 iBrain, Université de Tours, Inserm, 37032 Tours, France
| | | | - Hugh J Byrne
- FOCAS Research Institute, Technological University Dublin, Kevin Street, Dublin 8, Ireland
| | - Elhadi Mohammed
- Department of Pharmacognosy, Faculty of Pharmacy, University of Gezira, Sudan
| | - Igor Chourpa
- Université François-Rabelais de Tours, EA 6295 Nanomédicaments et Nanosondes, 31 avenue Monge, 37200 Tours, France
| |
Collapse
|
13
|
Lê L, Berge M, Tfayli A, Baillet Guffroy A, Prognon P, Dowek A, Caudron E. Quantification of gemcitabine intravenous drugs by direct measurement in chemotherapy plastic bags using a handheld Raman spectrometer. Talanta 2018; 196:376-380. [PMID: 30683379 DOI: 10.1016/j.talanta.2018.11.062] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Revised: 11/17/2018] [Accepted: 11/19/2018] [Indexed: 11/28/2022]
Affiliation(s)
- L Lê
- U-Psud, Univ. Paris-Saclay, Lip(Sys)2 Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France; European Georges Pompidou Hospital (AP-HP), Pharmacy Department, 20 rue Leblanc, 75015 Paris, France.
| | - M Berge
- European Georges Pompidou Hospital (AP-HP), Pharmacy Department, 20 rue Leblanc, 75015 Paris, France
| | - A Tfayli
- U-Psud, Univ. Paris-Saclay, Lip(Sys)2 Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France
| | - A Baillet Guffroy
- U-Psud, Univ. Paris-Saclay, Lip(Sys)2 Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France
| | - P Prognon
- U-Psud, Univ. Paris-Saclay, Lip(Sys)2 Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France; European Georges Pompidou Hospital (AP-HP), Pharmacy Department, 20 rue Leblanc, 75015 Paris, France
| | - A Dowek
- European Georges Pompidou Hospital (AP-HP), Pharmacy Department, 20 rue Leblanc, 75015 Paris, France
| | - E Caudron
- U-Psud, Univ. Paris-Saclay, Lip(Sys)2 Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France; European Georges Pompidou Hospital (AP-HP), Pharmacy Department, 20 rue Leblanc, 75015 Paris, France
| |
Collapse
|
14
|
Jaccoulet E, Boughanem C, Auduteau L, Prognon P, Caudron E. UV spectroscopy and least square matching for high throughput discrimination of taxanes in commercial formulations and compounded bags. Eur J Pharm Sci 2018; 123:143-152. [DOI: 10.1016/j.ejps.2018.07.047] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Revised: 07/13/2018] [Accepted: 07/22/2018] [Indexed: 10/28/2022]
|
15
|
Lê L, Berge M, Tfayli A, Prognon P, Caudron E. Discriminative and Quantitative Analysis of Antineoplastic Taxane Drugs Using a Handheld Raman Spectrometer. BIOMED RESEARCH INTERNATIONAL 2018; 2018:8746729. [PMID: 30065947 PMCID: PMC6051283 DOI: 10.1155/2018/8746729] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 05/20/2018] [Accepted: 05/30/2018] [Indexed: 11/17/2022]
Abstract
This study was conducted to evaluate the ability of Raman spectroscopy (RS) to control antineoplastic preparations used for chemotherapy in order to ensure its physical and chemical qualities. Three taxane drugs: cabazitaxel (CBX), docetaxel (DCX) and paclitaxel (PCX) at therapeutic concentration ranges were analyzed using a handheld spectrometer at 785 nm. Qualitative and quantitative models were developed and optimized using a calibration set (n=75 per drug) by partial least square discriminant analysis and regression and validated using a test set (n=27 per drug). All samples were correctly assigned with an accuracy of 100%. Despite optimization, quantitative analysis showed limited performances at the lowest concentrations. The root mean square error of predictions ranged from 0.012 mg/mL for CBX to 0.048 mg/mL for DCX with a minimal coefficient of determination of 0.9598. The linearity range was validated from 0.175 to 0.30 mg/mL for CBX, from 0.40 to 1.00 mg/mL for DCX and from 0.57 to 1.20 mg/mL for PCX. Despite some limitations, this study confirms the potential of RS to control these drugs and also provides substantial advantages to secure the activity for healthcare workers. As a result of its rapidity and the uncomplicated use of a handheld instrument, RS appears to be a promising method to augment security of the medication preparation process in hospitals.
Collapse
Affiliation(s)
- Laetitia Lê
- U-Psud, Univ. Paris-Saclay, Lip(Sys), EA7357, UFR-Pharmacy, Châtenay-Malabry, France
- European Georges Pompidou Hospital (AP-HP), Pharmacy Department, Paris, France
| | - Marion Berge
- European Georges Pompidou Hospital (AP-HP), Pharmacy Department, Paris, France
| | - Ali Tfayli
- U-Psud, Univ. Paris-Saclay, Lip(Sys), EA7357, UFR-Pharmacy, Châtenay-Malabry, France
| | - Patrice Prognon
- U-Psud, Univ. Paris-Saclay, Lip(Sys), EA7357, UFR-Pharmacy, Châtenay-Malabry, France
- European Georges Pompidou Hospital (AP-HP), Pharmacy Department, Paris, France
| | - Eric Caudron
- U-Psud, Univ. Paris-Saclay, Lip(Sys), EA7357, UFR-Pharmacy, Châtenay-Malabry, France
- European Georges Pompidou Hospital (AP-HP), Pharmacy Department, Paris, France
| |
Collapse
|
16
|
Gilbert RE, Kozak MC, Dobish RB, Bourrier VC, Koke PM, Kukreti V, Logan HA, Easty AC, Trbovich PL. Intravenous Chemotherapy Compounding Errors in a Follow-Up Pan-Canadian Observational Study. J Oncol Pract 2018; 14:e295-e303. [PMID: 29676947 PMCID: PMC5952328 DOI: 10.1200/jop.17.00007] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose: Intravenous (IV) compounding safety has garnered recent attention as a result of high-profile incidents, awareness efforts from the safety community, and increasingly stringent practice standards. New research with more-sensitive error detection techniques continues to reinforce that error rates with manual IV compounding are unacceptably high. In 2014, our team published an observational study that described three types of previously unrecognized and potentially catastrophic latent chemotherapy preparation errors in Canadian oncology pharmacies that would otherwise be undetectable. We expand on this research and explore whether additional potential human failures are yet to be addressed by practice standards. Methods: Field observations were conducted in four cancer center pharmacies in four Canadian provinces from January 2013 to February 2015. Human factors specialists observed and interviewed pharmacy managers, oncology pharmacists, pharmacy technicians, and pharmacy assistants as they carried out their work. Emphasis was on latent errors (potential human failures) that could lead to outcomes such as wrong drug, dose, or diluent. Results: Given the relatively short observational period, no active failures or actual errors were observed. However, 11 latent errors in chemotherapy compounding were identified. In terms of severity, all 11 errors create the potential for a patient to receive the wrong drug or dose, which in the context of cancer care, could lead to death or permanent loss of function. Three of the 11 practices were observed in our previous study, but eight were new. Applicable Canadian and international standards and guidelines do not explicitly address many of the potentially error-prone practices observed. Conclusion: We observed a significant degree of risk for error in manual mixing practice. These latent errors may exist in other regions where manual compounding of IV chemotherapy takes place. Continued efforts to advance standards, guidelines, technological innovation, and chemical quality testing are needed.
Collapse
Affiliation(s)
- Rachel E Gilbert
- Independent consultant; The TECHNA Institute; Princess Margaret Cancer Centre; Canadian Association of Provincial Cancer Agencies; University of Toronto; North York General Hospital, Toronto, Ontario; Alberta Health Services, Edmonton, Alberta; CancerCare Manitoba, Winnipeg, Manitoba; and BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Melissa C Kozak
- Independent consultant; The TECHNA Institute; Princess Margaret Cancer Centre; Canadian Association of Provincial Cancer Agencies; University of Toronto; North York General Hospital, Toronto, Ontario; Alberta Health Services, Edmonton, Alberta; CancerCare Manitoba, Winnipeg, Manitoba; and BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Roxanne B Dobish
- Independent consultant; The TECHNA Institute; Princess Margaret Cancer Centre; Canadian Association of Provincial Cancer Agencies; University of Toronto; North York General Hospital, Toronto, Ontario; Alberta Health Services, Edmonton, Alberta; CancerCare Manitoba, Winnipeg, Manitoba; and BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Venetia C Bourrier
- Independent consultant; The TECHNA Institute; Princess Margaret Cancer Centre; Canadian Association of Provincial Cancer Agencies; University of Toronto; North York General Hospital, Toronto, Ontario; Alberta Health Services, Edmonton, Alberta; CancerCare Manitoba, Winnipeg, Manitoba; and BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Paul M Koke
- Independent consultant; The TECHNA Institute; Princess Margaret Cancer Centre; Canadian Association of Provincial Cancer Agencies; University of Toronto; North York General Hospital, Toronto, Ontario; Alberta Health Services, Edmonton, Alberta; CancerCare Manitoba, Winnipeg, Manitoba; and BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Vishal Kukreti
- Independent consultant; The TECHNA Institute; Princess Margaret Cancer Centre; Canadian Association of Provincial Cancer Agencies; University of Toronto; North York General Hospital, Toronto, Ontario; Alberta Health Services, Edmonton, Alberta; CancerCare Manitoba, Winnipeg, Manitoba; and BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Heather A Logan
- Independent consultant; The TECHNA Institute; Princess Margaret Cancer Centre; Canadian Association of Provincial Cancer Agencies; University of Toronto; North York General Hospital, Toronto, Ontario; Alberta Health Services, Edmonton, Alberta; CancerCare Manitoba, Winnipeg, Manitoba; and BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Anthony C Easty
- Independent consultant; The TECHNA Institute; Princess Margaret Cancer Centre; Canadian Association of Provincial Cancer Agencies; University of Toronto; North York General Hospital, Toronto, Ontario; Alberta Health Services, Edmonton, Alberta; CancerCare Manitoba, Winnipeg, Manitoba; and BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Patricia L Trbovich
- Independent consultant; The TECHNA Institute; Princess Margaret Cancer Centre; Canadian Association of Provincial Cancer Agencies; University of Toronto; North York General Hospital, Toronto, Ontario; Alberta Health Services, Edmonton, Alberta; CancerCare Manitoba, Winnipeg, Manitoba; and BC Cancer Agency, Vancouver, British Columbia, Canada
| |
Collapse
|
17
|
Affiliation(s)
- Garima Agrawal
- Department of Polymer and Process Engineering, Indian Institute of Technology Roorkee, Saharanpur Campus, Paper Mill Road, Saharanpur 247 001, Uttar Pradesh, India
| | - Sangram K. Samal
- Materials Research Centre, Indian Institute of Science, Bangalore 560 012, India
| |
Collapse
|
18
|
Chouquet T, Benoit G, Morand K. Analytical Control of Pediatric Chemotherapy Preparations with a UV-Raman Automaton: Results After 18 Months of Implementation and Development of A Suitable Method for Low Volume Preparations. PHARMACEUTICAL TECHNOLOGY IN HOSPITAL PHARMACY 2017. [DOI: 10.1515/pthp-2017-0021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
AbstractBackgroundIn France, control of chemotherapy preparations is highly recommended. Analytical control is a method of choice for identifying and quantifying drugs. Pediatric preparations, which often contain small quantities of drugs and are made in low final volumes were until then not analytically controlled. After the development and validation of a new sampling and assaying method for low volume chemotherapy preparations with an UV/Raman automaton (QCPrep +), the quality control results of the preparations intended for the patients were analyzed over a period of eighteen monthsMethodsThe results were studied by type of preparation (low and high volume), per molecule, manipulator, and conformity rates dispersion.ResultsOver the period, 7,548 controls were carried out, representing 87.7% of our production. 75.5% of these controls concerned low-volume preparations (<50mL). The overall conformity rate was 94.4%. The lowest conformity rates were found for vinca alkaloids, methotrexate and some rarely manipulated drugs (cisplatin, decitabine, epirubicin). The study of the results dispersion showed non-conformities increasing with low concentrations, specific to pediatrics. These results show the limits of analytical control for pediatric preparations. The low analytical sensitivity encountered for certain concentrations and drugs requires a complementary quality control tool, like camera or video. However this new analytical method allows us to improve the safety of the injectable chemotherapy circuit.ConclusionYoung patients can benefit from the same level of safety and quality as adult patients. Some critical points could be highlighted: the homogenization of the preparations, the analytical sensitivity of some drugs and human factors. This data allow us to focus our work on staff training, improving our calibration ranges and on the development of complementary control tools.
Collapse
|
19
|
Lê LMM, Berge M, Tfayli A, Zhou J, Prognon P, Baillet-Guffroy A, Caudron E. Rapid discrimination and quantification analysis of five antineoplastic drugs in aqueous solutions using Raman spectroscopy. Eur J Pharm Sci 2017; 111:158-166. [PMID: 28966101 DOI: 10.1016/j.ejps.2017.09.046] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Revised: 09/08/2017] [Accepted: 09/27/2017] [Indexed: 11/28/2022]
Abstract
The aim of this study was to assess the ability of Raman spectroscopy to discriminate and quantify five antineoplastic drugs in an aqueous matrix at low concentrations before patient administration. Five antineoplastic drugs were studied at therapeutic concentrations in aqueous 0.9% sodium chloride: 5-fluorouracil (5FU), gemcitabine (GEM), cyclophophamide (CYCLO), ifosfamide (IFOS) and doxorubicin (DOXO). All samples were packaged in glass vials and analyzed using Raman spectrometry from 400 to 4000cm-1. Discriminant analyses were performed using Partial Least Squares Discriminant Analysis (PLS-DA) and quantitative analyses using PLS regression. The best discrimination model was obtained using hierarchical PLS-DA models including three successive models for concentrations higher than the lower limit of quantification (0% of fitting and cross-validation error rate with an excellent accuracy of 100%). According to these hierarchical discriminative models, 90.8% (n=433) of external validation samples were correctly predicted, 2.5% (n=12) were misclassified and 6.7% (n=32) of the external validation set were not assigned. The quantitative analysis was characterized by the RMSEP that ranged from 0.23mg/mL for DOXO to 3.05mg/mL for 5FU. The determination coefficient (R2) was higher than 0.9994 for all drugs evaluated except for 5FU (R2=0.9986). This study provides additional information about the potential value of Raman spectroscopy for real-time quality control of cytotoxic drugs in hospitals. In some situations, this technique therefore constitutes a powerful alternative to usual methods with ultraviolet (UV) detection to ensure the correct drug and the correct dose in solutions before administration to patients and to limit exposure of healthcare workers during the analytical control process.
Collapse
Affiliation(s)
- Laetitia Minh Mai Lê
- U-Psud, Univ. Paris-Saclay, Lip(Sys)(2) Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France; European Georges Pompidou Hospital (AP-HP), Pharmacy Department, Paris, France.
| | - Marion Berge
- European Georges Pompidou Hospital (AP-HP), Pharmacy Department, Paris, France
| | - Ali Tfayli
- U-Psud, Univ. Paris-Saclay, Lip(Sys)(2) Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France
| | - Jiangyan Zhou
- U-Psud, Univ. Paris-Saclay, Lip(Sys)(2) Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France
| | - Patrice Prognon
- U-Psud, Univ. Paris-Saclay, Lip(Sys)(2) Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France; European Georges Pompidou Hospital (AP-HP), Pharmacy Department, Paris, France
| | - Arlette Baillet-Guffroy
- U-Psud, Univ. Paris-Saclay, Lip(Sys)(2) Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France
| | - Eric Caudron
- U-Psud, Univ. Paris-Saclay, Lip(Sys)(2) Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France; European Georges Pompidou Hospital (AP-HP), Pharmacy Department, Paris, France
| |
Collapse
|
20
|
Lagarce F. Centrally Prepared Cytotoxic Drugs: What Is the Purpose of Their Quality Control? PHARMACEUTICAL TECHNOLOGY IN HOSPITAL PHARMACY 2017. [DOI: 10.1515/pthp-2017-0006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
AbstractTo assess the quality of centrally prepared cytotoxics a global approach is being implemented by pharmacists. A risk analysis is performed, and then many in-process controls are proposed. The aseptic process and the material are also fully validated. Moreover the skills of pharmacy technicians are being checked and monitored over time. This short opinion paper discusses the place of in-process quality control within the quality system applied to cytotoxic preparations. It also discusses the pros and cons of analytical control of the final product versus continuous control of each preparation step by eye witness or an electronic device such as a camcorder. Finally the relevancy of controls is discussed in function of different cases and of the human and material resources available in the pharmaceutical technology cytotoxic unit.
Collapse
|
21
|
Chouquet T, Benoit G, Morand K. Implementation of Analytical Control of Low Volume Pediatric Cytotoxic Drugs Preparations using a UV/Raman Spectrophotometer. PHARMACEUTICAL TECHNOLOGY IN HOSPITAL PHARMACY 2016. [DOI: 10.1515/pthp-2016-0013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract: Pediatric chemotherapy preparations are usually not analytically controlled, for several reasons. First, they are generally made in syringe, which does not allow to take a sample without changing the final volume. Secondly, the percentage of the dose consecrated to control is important and finally low concentrations can cause sensitivity problems. This lack of quality control, greatly reduces the security of the chemotherapy circuit.: The main objective is to develop an analytical control to low volume pediatric preparations, made in syringes or in infusion bags with a final volume from 20 to 50 mL.: The development of analytical control automatons, like QCPrep+: Our protocol implies the overfilling with one milliliter of solvent followed by a sampling of one milliliter. The analysis is performed with 900 µL. Ten cytotoxic drugs commonly used in pediatric oncology have been validated according to ICH recommendations. The development of analytical control for low volume preparations allows young patients to benefit the same level of safety and quality than adult patients.
Collapse
|